Which FDA‑approved appetite suppressants are appropriate for weight loss in an adult patient, including dosing, contraindications, and monitoring?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FDA-Approved Appetite Suppressants for Weight Loss

Semaglutide 2.4 mg should be prioritized as first-line pharmacotherapy for weight loss in adults with obesity or overweight with weight-related complications, given its superior efficacy and favorable cardiovascular profile. 1

Medication Hierarchy

The most recent 2025 AACE guidelines stratify obesity medications into first-generation and second-generation agents, with semaglutide and tirzepatide representing second-generation, more effective options that should be prioritized when accessible 2.

First-Line: GLP-1 Receptor Agonists

Semaglutide 2.4 mg (Wegovy)

  • Dosing: Start 0.25 mg subcutaneously weekly, escalate monthly (0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg maintenance)
  • Efficacy: Produces the greatest weight loss among approved medications
  • Monitoring: Assess for nausea/vomiting (most common), monitor for pancreatitis and gallbladder disease
  • Contraindications: Personal/family history of medullary thyroid carcinoma, MEN2 syndrome, pregnancy/breastfeeding
  • Key advantage: Glucoregulatory benefits, approved for T2DM, gradual titration mitigates GI side effects 1

Liraglutide 3.0 mg (Saxenda)

  • Dosing: Start 0.6 mg daily subcutaneously, increase by 0.6 mg weekly to 3.0 mg maintenance
  • Similar profile to semaglutide but requires daily injection and produces less weight loss
  • Same monitoring and contraindications as semaglutide 1

Second-Line: Combination Agents

Phentermine/Topiramate ER (Qsymia)

  • Dosing: Start 3.75 mg/23 mg daily for 14 days, then 7.5 mg/46 mg daily; can escalate to 15 mg/92 mg maximum
  • Efficacy: Moderate weight loss (5.9-11.5% in trials)
  • Monitoring: Blood pressure and heart rate periodically; check for hypokalemia, metabolic acidosis, nephrolithiasis
  • Contraindications: Pregnancy (REMS program required—monthly pregnancy testing mandatory), glaucoma, untreated hyperthyroidism, cardiovascular disease, uncontrolled hypertension
  • Preferred for: Patients with comorbid migraines 1, 2
  • Critical pitfall: Topiramate is highly teratogenic—pregnancy prevention is non-negotiable 2

Naltrexone/Bupropion ER (Contrave)

  • Dosing: Start 8 mg/90 mg once daily, escalate weekly by one tablet to 16 mg/180 mg twice daily (32 mg/360 mg total daily)
  • Efficacy: 5.9-11.5% weight loss in completers
  • Monitoring: Blood pressure and heart rate, especially first 12 weeks
  • Contraindications: Seizure disorders, concurrent opioid use, pregnancy/breastfeeding
  • Preferred for: Patients attempting smoking cessation or with comorbid depression 1, 2
  • Critical pitfall: Avoid with fatty meals (increases drug levels); cannot use with opioids 2

Third-Line Options

Phentermine (monotherapy)

  • Dosing: 15-37.5 mg daily
  • FDA-approved for short-term use only (<12 weeks), though AGA conditionally recommends with lifestyle modifications 1
  • Monitoring: Blood pressure and heart rate
  • Lower cost option but less evidence for long-term use 2

Orlistat (Xenical, Alli)

  • AGA suggests AGAINST routine use due to minimal weight loss benefit and significant GI adverse effects 1
  • Dosing: 120 mg three times daily with meals
  • Monitoring: Requires daily multivitamin with fat-soluble vitamins (A, D, E, K) taken 2 hours apart from orlistat
  • Only consider if: Patient highly values small weight loss and tolerates GI effects 1

Clinical Algorithm for Selection

  1. Start with semaglutide 2.4 mg for most patients—greatest efficacy and cardiovascular benefits 1

  2. If cost-prohibitive or GLP-1 intolerant, use step-therapy approach with first-generation agents 2:

    • Migraines present: Phentermine/topiramate ER
    • Depression or smoking cessation: Naltrexone/bupropion ER
    • Cardiovascular disease/uncontrolled HTN: Avoid phentermine-containing products; use naltrexone/bupropion ER or liraglutide
  3. Absolute contraindications across all agents: Pregnancy and breastfeeding 2

Universal Monitoring Requirements

  • Baseline: Pregnancy test (women of childbearing potential), blood pressure, heart rate, comprehensive metabolic panel
  • Ongoing:
    • Blood pressure and heart rate with sympathomimetic agents (phentermine-containing, naltrexone/bupropion)
    • Signs/symptoms of pancreatitis and gallbladder disease with GLP-1 RAs
    • Electrolytes with phentermine/topiramate (hypokalemia, metabolic acidosis)
    • Monthly pregnancy testing with phentermine/topiramate ER 1, 2

Critical Pitfalls to Avoid

  • Do not use phentermine/topiramate without REMS compliance—teratogenicity risk is substantial 2
  • Do not combine naltrexone/bupropion with opioids—blocks opioid efficacy 1
  • Do not prescribe GLP-1 RAs without counseling on pancreatitis/gallbladder symptoms—increased risk documented 1
  • Do not use phentermine-containing products in uncontrolled hypertension or cardiovascular disease 1
  • All medications require long-term use—obesity is a chronic disease requiring sustained treatment 3

References

Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Research

Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.

Endocrinology and metabolism clinics of North America, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.